Primidone

Evidence Level: L5

Predicted Indications: 3

Primidone

Pharmacist Assessment Report

Primidone: Trigeminal nerve neoplasm

One-Sentence Summary

Primidone is an anticonvulsant originally used to treat epilepsy, including generalized tonic-clonic seizures, partial epilepsy and Lennox-Gastaut syndrome. The TxGNN model (deep learning) predicts it may be effective for trigeminal nerve neoplasm, but there are currently 0 clinical trials and 0 publications supporting this top-ranked prediction. The score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Trigeminal nerve neoplasm
TxGNN Prediction Score	0.9999
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 2 of 2)
Number of DINs	2 (marketed: 2)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, primidone is an established anticonvulsant (it is partly metabolized to phenobarbital), its efficacy in epilepsy is well recognized, and its action is aimed at reducing neuronal hyperexcitability.

For the top-ranked prediction, trigeminal nerve neoplasm, no mechanistic link to an anticonvulsant is evident. No antineoplastic mechanism is known for primidone, so the high score should be treated as a hypothesis, not as evidence of efficacy. The score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.

The lower-ranked predictions are more plausible mechanistically. Several are reflex seizure disorders within the epilepsy spectrum (audiogenic seizures, micturition-induced seizures, eating seizures, startle epilepsy, orgasm-induced seizures, thinking seizures and reading seizures). These are close to the approved indications, and so are largely redundant with them. Trigeminal neuralgia, the only other prediction with a plausible link, is already treated mainly with carbamazepine, an established standard of care. Beta-ketothiolase deficiency, a metabolic disorder, has no evident link to primidone.

Clinical Trial Evidence

Currently no related clinical trials registered for trigeminal nerve neoplasm, nor for any of the other top-10 predicted indications.

Literature Evidence

Currently no related literature available for trigeminal nerve neoplasm.

For context, the literature found for lower-ranked predictions is indirect only:

PMID	Year	Type	Journal	Key Findings
15246950	2004	Review	Epileptic Disord	Antiepileptic drugs for indications other than epilepsy; evidence mostly from case series and small trials (trigeminal neuralgia)
14249886	1964	Preclinical (animal)	Biull Eksp Biol Med	Audiogenic convulsions in animals after prior primidone administration
184518	1976	Preclinical (mouse)	Neurol Psychiatr	Effect of phenobarbital, diphenylhydantoin and primidone on brain enzyme activity in audiogenic epilepsy in mice
8891399	1995	Review	Clin Neurosci	Primidone (500–1,000 mg/day) is among the most useful drugs for cortical myoclonus (cited for reading seizures)
4525036	1974	Case report (veterinary)	J Am Vet Med Assoc	Long-term primidone therapy in a dog (eating seizures)
8548670	1995	Case report	Chin Med J (Taipei)	Startle epilepsy presenting as drop attacks; primidone use not shown in the title

None of these is a controlled study of primidone in the predicted indication.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
00399310	PRIMIDONE	Not specified	Not specified
00396761	PRIMIDONE	Not specified	Not specified

Safety Considerations

Contraindications suggested by the knowledge graph (these come from drug-disease edges, not from package insert text):

Blood disorders: thrombocytopenia, neutropenia, agranulocytosis, leukopenia, pancytopenia, anaemia (including macrocytic anaemia) and several congenital neutropenia syndromes
Porphyria (including inherited porphyria)
Kidney disease and liver disease
Sleep-related breathing disorders: obstructive sleep apnoea and congenital central hypoventilation syndrome
Psychiatric and substance-related conditions: anxiety disorder, neurotic disorder, dysthymic disorder and substance abuse/dependence
Gallbladder disease and pyoureter

Drug interactions: 100 interactions were found in the DDI query. Examples:

Major: morphine, eliglustat
Moderate: doxycycline, hydrocortisone, dexamethasone, betamethasone, triamcinolone, cholecalciferol, calcitriol, pioglitazone, bupropion, aprepitant, metronidazole, canagliflozin, saxagliptin, dronabinol
Minor: cimetidine

Package insert warnings and contraindications were not available. Please refer to the package insert for the full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction, trigeminal nerve neoplasm, rests on a model score alone, with no trials, no literature and no known antineoplastic mechanism for primidone. Among the lower-ranked predictions, the reflex seizure indications overlap with the existing epilepsy use and are supported only by old, indirect or animal evidence. Trigeminal neuralgia is a research question, since carbamazepine is already the standard treatment.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications, which are required for safety screening
Mechanism of action data for primidone
Any primary evidence, preclinical or clinical, linking primidone to trigeminal nerve neoplasm, or a decision to evaluate the more plausible indications (such as trigeminal neuralgia) instead
Approved indication text and dosage forms for the two Canadian DINs
A drug-interaction review, particularly for the major interactions with morphine and eliglustat
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.